Intestinal P-glycoprotein exports endocannabinoids to prevent inflammation and maintain homeostasis by Szabady, Rose L. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2018-08-31 
Intestinal P-glycoprotein exports endocannabinoids to prevent 
inflammation and maintain homeostasis 
Rose L. Szabady 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Amino Acids, Peptides, and Proteins Commons, Cells Commons, Cellular and Molecular 
Physiology Commons, Digestive System Diseases Commons, Gastroenterology Commons, Hemic and 
Immune Systems Commons, Lipids Commons, and the Pathological Conditions, Signs and Symptoms 
Commons 
Repository Citation 
Szabady RL, Louissaint C, Lubben A, Xie B, Reeksting S, Tuohy C, Demma Z, Foley S, Faherty CS, Llanos-
Chea A, Olive AJ, Mrsny RJ, McCormick BA. (2018). Intestinal P-glycoprotein exports endocannabinoids to 
prevent inflammation and maintain homeostasis. Open Access Articles. https://doi.org/10.1172/
JCI96817. Retrieved from https://escholarship.umassmed.edu/oapubs/3574 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Intestinal P-glycoprotein exports
endocannabinoids to prevent inflammation and
maintain homeostasis
Rose L. Szabady, … , Randall J. Mrsny, Beth A. McCormick
J Clin Invest. 2018;128(9):4044-4056. https://doi.org/10.1172/JCI96817.
 
Neutrophil influx into the intestinal lumen is a critical response to infectious agents, but is
also associated with severe intestinal damage observed in idiopathic inflammatory bowel
disease. The chemoattractant hepoxilin A3, an eicosanoid secreted from intestinal epithelial
cells by the apically restricted efflux pump multidrug resistance protein 2 (MRP2), mediates
this neutrophil influx. Information about a possible counterbalance pathway that could signal
the lack of or resolution of an apical inflammatory signal, however, has yet to be described.
We now report a system with such hallmarks. Specifically, we identify endocannabinoids as
the first known endogenous substrates of the apically restricted multidrug resistance
transporter P-glycoprotein (P-gp) and reveal a mechanism, which we believe is novel, for
endocannabinoid secretion into the intestinal lumen. Knockdown or inhibition of P-gp
reduced luminal secretion levels of N-acyl ethanolamine–type endocannabinoids, which
correlated with increased neutrophil transmigration in vitro and in vivo. Additionally, loss of
CB2, the peripheral cannabinoid receptor, led to increased pathology and neutrophil influx
in models of acute intestinal inflammation. These results define a key role for epithelial cells
in balancing the constitutive secretion of antiinflammatory lipids with the stimulated
secretion of proinflammatory lipids via surface efflux pumps in order to control neutrophil
infiltration into the intestinal lumen and maintain homeostasis in the healthy intestine.
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Introduction
The healthy intestine is remarkable for the absence of an inflam-
matory response in the presence of dense microbial colonization. 
Maintenance of homeostasis requires a dynamic, regulated bal-
ance among the host immune response, resident microbiota, and 
the thin epithelial layer that separates them. While maintaining 
a state of noninflammation, however, the immune system must 
remain poised to mount an inflammatory response upon exposure 
to pathogens. Dysregulation of this balance can have serious conse-
quences that may drive a variety of pathological conditions, includ-
ing inflammatory bowel disease (IBD) (1). Epithelial cells serve as 
a physical barrier to microbial penetration and provide a sentinel 
system to warn immune cells of pathogen exposure by secreting 
neutrophil chemoattractants, placing them in a critical position to 
regulate the balance between pro- and antiinflammatory states. 
One of the first events associated with induction of a proinflamma-
tory state is the transepithelial migration of neutrophils from the 
submucosal compartment to the lumen of the epithelium: a 1-way 
cellular-trafficking process that allows neutrophils to engage with 
pathogens before they can enter the host.
Neutrophil recruitment to access the epithelial lumen must 
occur via a carefully regulated multistep cascade of events, as 
the powerful effectors released by recruited neutrophils potently 
kill bacteria but lack specificity and thus can also cause severe 
collateral tissue damage. Basolateral release of IL-8 by epithe-
lial cells stimulates recruitment of neutrophils out of the vas-
culature and into the lamina propria underlying the epithelial 
layer (1). However, IL-8 is unable to mediate the final step, in 
which neutrophils migrate from the basolateral (serosal) sur-
face of the epithelium to its apical (luminal) surface. We previ-
ously identified an innate immune pathway in intestinal epi-
thelial cells that functions to establish the chemo tactic gradient 
required for neutrophils to move from the submucosal space 
to the lumen of the gut, where subsequent activation leads to 
inflammatory outcomes. We defined a critical role in this process 
for the eicosanoid hepoxilin A3 (HxA3) (2), a potent neutrophil 
chemoattractant that is secreted from the apical surface of the 
epithelium via the multi-drug resistance protein 2 (MRP2) efflux 
pump (3). Polarized expression of MRP2 and the activity of this 
MRP2/HxA3 axis are greatly increased during inflammatory 
states, and this pathway is nonredundant with other chemoattrac-
tants driving neutrophil recruitment, such as IL-8. Additionally, 
we have shown that the MRP2/HxA3 axis is a conserved mecha-
nism at mucosal surfaces and can drive a damaging inflammatory 
response with severe pathological consequences (3–11). Clinical 
evidence further indicates that the MRP2/HxA3 pathway is acti-
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proinflammatory eicosanoid HxA3 is upregulated (13). We then 
demonstrated that MRP2 transports HxA3 into the intestinal 
lumen, establishing a chemotactic gradient biased toward the 
lumen that directs migration of neutrophils from the basolateral 
space across the epithelium, a critical step in the inflammatory 
process (2, 3). Having shown that this MRP2/HxA3 pathway is 
conserved during infection with multiple pathogens in both lung 
and intestinal epithelia (5, 7, 14), we sought to determine whether it 
also drives inflammation in the absence of infection; certain forms 
of IBD as well as several other clinically important human diseases 
(e.g., rheumatoid arthritis, psoriasis) are characterized by exces-
sive neutrophilic inflammation with no known infectious agent.
Treatment of mice with dextran sodium sulfate (DSS) induces 
acute colonic inflammation characterized by epithelial damage and 
neutrophil influx (15). Semiquantitative liquid chromatography– 
dual mass spectrometry (LC-MS/MS) analysis of colonic mucosal 
scrapings revealed that DSS treatment strongly induced secretion 
of HxA3 at the epithelial surface (Figure 1A). To confirm that this 
increased HxA3 contributes to disease, HxA3 secretion was specifi-
cally blocked via inhibition of MRP2 using probenecid (3). We chem-
ically conjugated probenecid to periodate-oxidized 40 kDa dextran 
through a reductive amidation reaction to produce a high molecular 
weight, hydrophilic material that would be essentially restricted to 
the apical surface of the intestine following its intrarectal admin-
vated in ulcerative colitis (UC) and Crohn disease (CD) patients 
(3), possibly due to aberrant regulation of signaling pathways.
Transepithelial migration is specifically associated with 
diminished barrier function, and while neutrophils in the lumen 
may kill pathogenic microbes, their sustained activity can cause 
intestinal damage. In fact, disruption of the final transmigration 
step in mice results in the basolateral collection of neutrophils 
without apparent damage, emphasizing the critical nature of 
transepithelial migration in neutrophil-driven pathology (12). We 
hypothesize that the MRP2/HxA3 axis forms the proinflammatory 
arm of a dynamically regulated system in which inflammatory 
pathways that activate responses to pathogens or aberrant signals 
are balanced against antiinflammatory pathways that suppress 
neutrophil responses in the context of normal commensal coloni-
zation. We therefore investigated the mechanisms by which epi-
thelial cells regulate transepithelial neutrophil migration during 
homeostasis and inflammation.
Results
We previously observed that epithelial cells dramatically increase 
surface expression of the membrane ABC transporter MRP2 in 
response to infection with a variety of pathogens including Sal-
monella typhimurium (3). Concurrent with this increased surface 
MRP2 expression, the intracellular biosynthetic pathway of the 
Figure 1. HxA3 drives inflammation during DSS colitis. (A) Mucosal scrapings from C57BL/6 WT 
mice (n = 10) treated with 3% DSS for 7 days were enriched for lipids, and the amount of HxA3 
was quantified by LC-MS/MS. *P = 0.050. (B–I) C57BL/6 mice were treated with 3% DSS for 7 
days and sacrificed at day 9. Starting at day 4, daily rectal administration of PBS control (vehicle) 
or 1 mM probenecid conjugate was performed. **P = 0.001, Mann-Whitney 1-tailed nonparametric 
U test. All data are shown as mean ± SEM. n = 10 mice per group. (C and D) Paraffin-embedded 
sections of mid and distal colon were stained for H&E and scored by a trained investigator 
blinded to sample identity. *P = 0.026. Arrow highlights accumulation of neutrophils in intestinal 
lumen. Original magnification, ×20. (E and F) MPO activity was measured by ADHP assay over 8 
minutes from (E) feces (*P = 0.044) or (F) colonic tissue and slopes calculated by linear regression 
(P = 0.362). For tissue, slopes were normalized to total protein content. (G–I) Total lamina propria 
leukocytes were isolated and stained for flow cytometry. Neutrophils were characterized as live/
CD45+CD11bhiLy6G+. (G) Percentage of neutrophils (NS, P = 0.193), (H) number of neutrophils (NS,  
P = 0.259), and (I) representative plots of neutrophils in colon tissue.
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In parallel with increased MRP2 
levels, another luminal ABC trans-
porter restricted to the luminal epi-
thelial surface, P-glycoprotein (P-gp), 
is actively reduced at the epithelial 
surface by Salmonella typhimurium 
(16, 17), the significance of which was 
previously unclear. P-gp is a multidrug 
transporter known to efflux small neu-
tral or positively charged hydrophobic 
compounds (18). Defects in P-gp 
expression or function are associated 
with IBD: decreased P-gp expression 
is observed in the epithelium of IBD 
patients, and single-nucleotide poly-
morphisms in the MDR1 gene encoding 
P-gp are associated with increased IBD 
risk (19–21). Further, mice lacking the 
Mdr1a gene that encodes P-gp develop 
spontaneous intestinal inflammation 
(22, 23). Evidence correlating reduced 
P-gp function with inflammation, com-
bined with the hydrophobic nature of 
known exogenous P-gp substrates, 
led us to hypothesize that P-gp might 
secrete endogenous bioactive lipids 
that could serve to antagonize HxA3-
mediated neutrophil transepithelial 
migration. We therefore analyzed the 
P-gp–dependent secreted lipidome of 
homeostatic epithelial cells to iden-
tify lipids capable of inhibiting HxA3- 
mediated neutrophil migration.
Supernatants collected from the 
apical surface of noninflamed T84 colonic epithelial cell monolay-
ers inhibited primary human neutrophil transmigration stimulated 
by HxA3 in an in vitro assay; we termed the unknown compound(s) 
in this preparation activity modulating epithelial neutrophil dis-
course (AMEND). Similar spent media collected from the basal 
compartment of T84 cell monolayers failed to exhibit AMEND 
activity. Subsequent size fractionation of crude AMEND prepara-
tions using ultrafiltration demonstrated AMEND to be less than 
1 kDa. An extensive series of BAKERBOND Sep-Pak extraction 
columns were tested to further characterize the AMEND activity. 
Outcomes of these matrix interaction studies suggested AMEND 
as having a lipophilic character (Supplemental Table 1). Notably, 
AMEND bound strongly to the Narc-2 matrix, used for the capture 
and elution of active agents in marijuana (24). The resulting opti-
mized AMEND collection protocol involved ultrafiltration of cell 
supernatants to isolate compounds smaller than 1 kDa, followed 
by lipid enrichment using reversed-phase C18 chromatography, 
yielding a fraction capable of inhibiting primary human neutrophil 
migration stimulated by HxA3 in a cell-free in vitro assay (Figure 
2A). To confirm that AMEND is specifically secreted by P-gp, we 
created stable knockdown human T84 epithelial cell lines using 
shRNA to target MDR1 and confirmed reduction of P-gp expres-
sion by Western blot (Supplemental Figure 2). Enriched superna-
istration in order to target luminal MRP2 and minimize systemic 
exposure. We confirmed that this probenecid-dextran conjugate 
was functional in vitro in inhibiting neutrophil migration in a Sal-
monella infection assay (Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI96817DS1). In vivo, inhibition of the MRP2/HxA3 pathway by 
intrarectal administration of the probenecid-dextran conjugate sig-
nificantly reduced intestinal path ology and colon shortening induced 
by DSS (Figure 1, B–D); though not shown, the histopathology score 
of mice without DSS was measured as 0. Analysis of colon histo-
pathology revealed that mice treated with the probenecid-dextran 
conjugate had reduced neutrophil infiltration into the colonic lumen 
(Figure 1, C and D; the vehicle cohort had a histopathology score of 
8.5, whereas the probenecid conjugate had a histopathology score of 
4.5), which was confirmed by a significant reduction in fecal sample 
myeloperoxidase (MPO) levels (Figure 1E). Conversely, quantita-
tion of neutrophils in the lamina propria during DSS-induced influx 
revealed no significant difference with probenecid treatment (Figure 
1, F–I), indicating that treatment primarily blocked migration across 
the epithelium into the lumen. These findings are consistent with 
other studies of the MRP2/HxA3 pathway and suggest that neutro-
phil transepithelial migration is particularly important in exacerbat-
ing inflammatory pathology.
Figure 2. Epithelial cells secrete P-gp–dependent ECs that inhibit neutrophil migration. (A) Supernatants 
from T84 epithelial monolayers were enriched for lipids and tested for the ability to inhibit HxA3-induced 
migration in a 96-well modified Boyden chamber assay. In order to compare across experiments with 
different donors, migration values within individual experiments were normalized to enriched HxA3 with 
vehicle treatment. For A–C, data are shown as mean ± SEM of 3 independent experiments. *P < 0.05: ***P 
< 0.01, 1-way ANOVA. (B) Performed as in A, with supernatants from cell lines expressing different shRNA 
constructs to knock down P-gp expression (B4-MDR1 and B5-MDR1). (C) Performed as in A, but prior to 
use in the migration assays, enriched T84 supernatants were pretreated with FAAH or MAGL at 37°C for 
30 minutes. (D) Lipid-extracted T84 supernatants from control or 2 separate MDR1-knockdown cell lines 
(B4 and B5) were subjected to electrospray ionization MS. AEA-d8 was included in each sample to allow 
quantitative comparisons between samples and was used to calculate relative units of each EC. Individual 
ECs were normalized to the relative units in the scrambled control condition.
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receptors GPR55 and GPR119 (27, 28). Potential 
interplay between these cannabinoid receptors 
is complex and the functional roles of each in 
the context of intestinal inflammation are still 
poorly understood (29, 30). The 2 main classes of 
eicosanoid-type ECs are N-acyl ethanolamines 
(NAEs) and monoacylglycerols (MAGs), which 
are metabolized by fatty acid amide hydrolase 
(FAAH) and monoacylglycerol lipase (MAGL), 
respectively (31, 32). To determine whether 
AMEND activity is provided by ECs, we exam-
ined its sensitivity to these enzymes. Treatment 
of enriched AMEND with FAAH completely 
eliminated the inhibitory activity of AMEND, 
whereas treatment with MAGL did not signifi-
cantly affect the ability of AMEND to inhibit 
HxA3-induced migration (Figure 2C), suggesting 
that AMEND belongs to the NAE class. To con-
firm the specificity of enzyme treatment, we per-
formed a similar experiment with the migration-
inhibiting non-EC lipid lipoxin A4, which was 
not sensitive to deactivation by FAAH or MAGL 
(Supplemental Figure 4).
We performed MS to identify AMEND 
components secreted from the apical epithelial 
surface in a P-gp–dependent manner. First, 
luminal secretions were collected from polar-
ized monolayers of T84 cells with and without 
verapamil treatment to block P-gp function. 
Unique peaks, identified by comparison of peak 
profiles of luminal contents of these 2 treat-
ments separated using C18 reversed phase high- 
performance LC protocol, were found to have 
masses consistent with the H+ and Na+ adduct 
masses of known ECs, specifically, anandamide 
(AEA) (Supplemental Figure 5). We next per-
formed a semiquantitative MS analysis, comparing 
supernatants obtained from control and MDR1- 
knockdown P-gp–deficient T84 intestinal epithe-
lial cells. Samples were spiked with deuterated AEA-d8 as an internal 
MS standard prior to enrichment of AMEND activity by ultrafiltra-
tion and reversed phase C18 chromatography as above prior to being 
subjected to high-resolution MS. H+ and Na+ adduct masses consis-
tent with AEA, oleoyl ethanolamide (OEA), and palmitoyl ethanol-
amide (PEA) were reduced in the absence of P-gp expression (Fig-
ure 2D and Supplemental Table 3). These ECs all belong to the NAE 
class; other lipids of the MAG class of ECs, including 2-arachidonoyl 
glycerol (2-AG) and noladin ether (NE), were present at similar or 
even increased amounts in the absence of P-gp (Figure 2D and Sup-
plemental Table 3). These results are consistent with AMEND being 
enzymatically susceptible to FAAH more than MAGL and support 
the hypothesis that P-gp specifically secretes NAE-class ECs.
We next tested purified ECs in the in vitro HxA3-induced neu-
trophil migration assay. Owing to the possibility that additional 
EC species were present in the original AMEND material, but 
not detected by MS analysis, a wide panel of commercially avail-
able purified ECs were tested. Only AEA, OEA, and α-linolenoyl 
tants from P-gp–deficient cells lacked AMEND activity and failed 
to inhibit neutrophil migration (Figure 2B). Similar results (Sup-
plemental Figure 3) were obtained following treatment of WT T84 
cells with verapamil, an inhibitor of P-gp (25).
To identify AMEND components responsible for inhibition 
of neutrophil transmigration, we first undertook a target-oriented 
approach to probe for receptor activation. Enriched AMEND was 
screened for both agonist and antagonist activity against a GPCR 
panel, using an assay for β-arrestin activity that is independent of 
G protein subtype (26). Consistent with its role as an inhibitor of 
neutrophil transmigration, AMEND displayed primarily antago-
nist activity at GPCRs, including several known chemoattractant 
receptors (Supplemental Table 2). Importantly, the strongest signal 
observed was for agonist activity at CB2, the peripheral cannabi-
noid receptor, suggesting that AMEND is composed of one or more 
endocannabinoid (EC) lipids.
ECs are defined by their activity at the classical cannabinoid 
receptors CB1 and CB2 as well as more recently described atypical 
Figure 3. P-gp–dependent apical secretion of ECs inhibits neutrophil migration. (A) Commer-
cially available ECs and related compounds were tested in the 96-well migration assay, with AEA, 
OEA, and α-LEA significantly suppressing neutrophil movement. Compounds were used at the 
highest concentration at which they were soluble in PBS. Data are shown as mean ± SEM of at 
least 3 independent experiments. *P < 0.05; **P < 0.01, 1-way ANOVA. (B) Confluent 2D human 
intestinal organoid cultures were used to examine apical secretion of AEA over a 6-hour time 
course with and without 50 μM verapamil (apical untreated, apical with verapamil), with levels 
being reported as average of triplicate measurements (± SD) normalized to time 0 values. Increas-
ing apical compartment levels of AEA over time were suppressed by the presence of 50 μM  
verapamil. Data are shown as mean ± SD from 3 independent experiments with 12–24 techni-
cal replicates in each experiment. *P < 0.01; **P < 0.001, unpaired t test. (C) The levels of AEA 
present in the basal compartment of confluent 2D human intestinal organoid cultures remained 
relatively constant over this same 6-hour time course, but were reduced in cultures treated with 
50 μM verapamil. Relative changes in the basal compartment AEA levels were measured at 0 
and 6 hours, with (white bars) and without (black bars) 50 μM verapamil addition. AEA levels 
are reported as normalized to time 0 values. Data are shown as mean ± SD from 3 independent 
experiments with 12–24 technical replicates in each experiment. *P < 0.01, unpaired t test.
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to regulate CB2 function, highlighting the complexity of their role 
or roles in inhibiting HxA3-mediated neutrophil migration. Thus, 
further investigations are required to reveal the nature of such 
intricate pharmacological interactions.
Since our studies have focused on how inflammatory signals 
regulate the transmigration of neutrophils from the basolateral 
compartment to the intestinal lumen, we hypothesize that such a 
system requires a biased release of agents to establish a chemical 
gradient from the apical epithelial surface. In support of this 
hypothesis, we have previously shown that the MRP2 transport 
pump involved in regulating the efflux of HxA3 from the apical sur-
face is restricted to this cell region to allow the establishment of 
such a gradient (2). Indeed, this prior work used human intestinal 
xenographs to show that the biology we are focusing on should be 
present in humans in vivo. To therefore extend the clinical signifi-
cance of these findings herein, we chose to follow the pattern of 
AEA release, as the AMEND prototype, within cell supernatants 
collected from the apical or basolateral compartment of healthy 
human-derived organoid (colonoid) epithelial monolayers grown 
in a 2D format (see Methods) 
in the absence or presence of 
the P-gp inhibitor verapamil. 
The apical and basal com-
partments of the 2D colonoid 
monolayers were exposed 
to verapamil as a standard 
method to inhibit the efflux 
of substrates by P-gp that is 
selectively expressed at the 
apical surface of intestinal epi-
thelial cells.
As shown in Figure 3B, the 
relative concentration of AEA 
increased in the apical com-
partment of the 2D colonoid 
cultures over the 6-hour study 
time course, but this increase 
was blocked by verapamil. 
However, AEA present in the 
basal compartment at the 
ethanolamide (α-LEA) exhibited significant inhibitory activity, 
identifying these NAEs as putative AMEND components (Figure 
3A). While other EC types have been reported as affecting neu-
trophil function in vitro (33, 34), we conclude that only NAE-type 
ECs are capable of specifically inhibiting HxA3-mediated neu-
trophil migration. Additional experiments were performed using 
mixtures of synthetic AEA, OEA, and α-LEA to determine their 
role in CB2-related effects of AMEND. Unsurprisingly, we found 
that these NAE-type ECs, when tested individually as well as in 
combinations, failed to directly act as CB2 receptor agonists; only 
AEA showed some activity and this was approximately 10-fold 
less active than 2-AG (Supplemental Table 4). Consistent with this 
observation, we screened for CB2 activity using NADA (a potent 
endogenous cannabinoid and vallinoid receptor agonist) and 
GP1a (a selective CB2 receptor agonist) as well as JTE 907 (a selec-
tive CB2 receptor inverse agonist); only JTE 907 showed signs of 
activity (Supplemental Figure 6). Taken together, these experi-
ments reveal the possibility that AEA, OEA, and α-LEA may not 
function as direct CB2 receptor agonists, but rather act indirectly 
Figure 4. AMEND is present in mouse intestine. (A) Colonic scrapings from 5 WT or Mdr1a–/– FVB mice were pooled, enriched for lipids, and tested in the 
96-well migration assay as in Figure 2. Data are shown as mean ± SEM from 3 independent experiments. **P < 0.01, 1-way ANOVA. (B) Indicated sample was 
pretreated with FAAH for 30 minutes at 37°C. *P = 0.01. (C) Intestinal mucosal scrapings from WT and Mdr1a–/– FVB mice were lipid extracted (modified Folch 
method) and analyzed by MS. Mice were pooled in groups of 3. Data shown are from 3 pooled groups. Semiquantitative analysis was performed as in Figure 2.
Figure 5. Signaling through CB2 contributes to AMEND inhibition of neutrophil migration. Neutrophils were isolated 
from the BM of WT or Cnr2–/– (CB2KO) mice and allowed to migrate across Salmonella-infected epithelial monolayers. 
SL, Salmonella. (A) Neutrophil migration was tested in the presence of enriched AMEND (AM). *P < 0.05. (B) Neutro-
phil migration was tested in the presence of purified ECs. *P < 0.05; **P < 0.01. Data are shown as mean ± SD from 3 
independent experiments. Comparison of groups was performed by Mann-Whitney nonparametric U test.
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beginning and end of this 6-hour time did not change, although 
such levels were reduced in 2D cultures treated with verapamil 
(Figure 3C). The constant level of AEA over time in the basal 
supernatants suggests that the amount of AEA reaching the basal 
compartment is dependent on paracellular diffusion from the api-
cal compartment and not an efflux from the basolateral surface 
of these 2D cultures, as we failed to observe an increase in AEA 
levels over this time period. Thus, there appears to be a balance 
between the rate of consumption and/or degradation of AEA at 
the basolateral surface of enterocytes and the egress of AEA from 
the apical compartment. Reduction in basal AEA levels in the 
verapamil-treated cultures likely reflects the reduced input rate to 
AEA via the paracellular route from the apical compartment with-
out a coordinated change in the rate of consumption and/or deg-
radation of AEA. Overall, these results are consistent with efflux of 
AEA by apically expressed P-gp, with its subsequent redistribution 
across the epithelium to suppress transmigration of neutrophils by 
direct interaction with these cells. Levels of 2-AG in the apical and 
basal compartment of this 2D monolayer model of healthy human 
intestine were below the level of detection.
A selective mechanism for EC transport out of cells had not 
been previously identified, although a putative membrane pro-
tein capable of bidirectional transport of AEA and 2-AG has been 
hypothesized (35). Having now established P-gp as an apical cell 
membrane efflux pump that exports NAE-type ECs in cultured 
epithelial cells, we sought to confirm this pathway in the intes-
tine. Mucosal scrapings from the colons of WT and P-gp deficient 
(Mdr1a–/–) mice were enriched for AMEND and evaluated for their 
Figure 6. CB2-deficient mice are vulnerable to severe intestinal inflammation with increased neutrophil transmigration. WT or Cnr2–/– mice were treated 
with 3% DSS for 7 days and sacrificed at day 9. (A) Weights are shown as percentage of day 0 (D0) weight. n = 25 WT; n = 24 Cnr2–/– mice. **P < 0.01; ***P < 
0.001. (B and C) Histopathology of mid and distal colon as in Figure 1. Arrows highlight accumulation of neutrophils in intestinal lumen. *P = 0.021. Original 
magnification, ×20. (D) Fecal MPO activity. n = 14 WT; n = 12 Cnr2–/– mice. **P = 0.008. (E) Tissue MPO activity. n = 13 WT; n = 11 Cnr2–/– mice. NS, P = 0.471. 
(F) Number (NS, P = 0.482) and (G) percentage (NS, P = 0.095) of tissue neutrophils by flow cytometry analysis. (H) Representative plots of lamina propria 
neutrophils. (F–H) n = 13 WT; n = 12 Cnr2–/– mice. (I–K) WT or Cnr2–/– mice were lethally irradiated and reconstituted with homologous or heterologous BM 
(donor→recipient). Following reconstitution for 7 weeks, mice were treated with DSS as above. (I) Weight curve. (J) Colon length. (K) Histopathology score.  
n = 7 WT→WT; n = 9 KO→WT; n = 9 WT→KO; n = 7 KO→KO mice. For all experiments, data are shown as mean ± SEM. Statistical analysis was performed with 
Mann-Whitney 1-tailed nonparametric U test. Histopathology scoring, MPO activity measurement, and flow cytometry analyses were performed as in Figure 1.
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ability to inhibit neutrophil migration. These ex vivo scrapings from 
WT mice inhibited in vitro neutrophil transmigration similarly to 
AMEND isolated from T84 cells, whereas scrapings from Mdr1a–/– 
mice lacked inhibitory AMEND activity (Figure 4A). When scrap-
ings from WT mice were pretreated with FAAH, they lost their 
inhibitory activity, confirming that these samples contained NAE 
ECs (Figure 4B). High-resolution MS revealed that similar NAE-
type ECs correlated with the presence of P-gp in vitro (Figure 
2D) and in vivo (Figure 4C) with the exception of PEA, which was 
equally abundant in samples obtained from both Mdr1a–/– and WT 
mice (Figure 4C and Supplemental Table 5). Although α-LEA was 
identified as an AMEND candidate in Figure 3B, it is not included 
in the LIPID MAPS database used for MS analysis, and so its 
potential dependence on P-gp export remains unknown.
The peripheral cannabinoid receptor CB2, which is expressed 
on immune cells, was identified as a potential AMEND target 
in our GPCR screen (Supplemental Table 2). While 2-AG is the 
canonical CB2 ligand, 2-AG, AEA, and other NAE-type ECs can 
activate CB1, CB2, and other non-CB receptors under varying 
conditions (36, 37). Additionally, mixed EC populations may have 
more complex effects, including the development of agonists or 
antagonists/inverse agonists when combined with other ECs 
(38–40). In order to determine whether CB2 signaling is required 
for inhibition of neutrophil migration by AMEND, we isolated 
neutrophils from WT and CB2-deficient (Cnr2–/–) mice. Migration 
of Cnr2–/–neutrophils across Salmonella-infected epithelial mono-
layers was significantly less impaired compared with WT neutro-
phil migration in the presence of enriched AMEND (Figure 5A). 
However, at higher concentrations, AMEND was able to partially 
inhibit migration of Cnr2–/–neutrophils, suggesting that signaling 
through receptors in addition to CB2 may contribute to AMEND 
activity. When experiments were performed with purified AEA, 
OEA, and α-LEA, CB2 expression contributed to inhibition of neu-
trophil transmigration by OEA and α-LEA, but not AEA (Figure 
5B), although mouse neutrophils in this assay were less susceptible 
to AEA inhibition for reasons we cannot yet explain.
We next investigated the potential for P-gp–mediated secretion 
of NAE-type ECs to functionally suppress HxA3-mediated intesti-
nal inflammation in vivo. In keeping with previous reports (23, 41), 
Mdr1a–/– mice, which would lack the capacity for P-gp–dependent EC 
secretion, developed spontaneous intestinal inflammation with age 
(data not shown) and were more susceptible to DSS-induced colitis 
Figure 7. The antiinflammatory P-gp/EC and proinflammatory MRP2/HxA3 pathways in the intestinal epithelium. In the homeostatic intestine, P-gp 
secretes ECs from the epithelial surface. Secreted NAEs act through the CB2 receptor on neutrophils to inhibit migration and maintain an antiinflamma-
tory state. During inflammation, P-gp is downregulated and the MRP2/HxA3 pathway is activated. Phospholipase A2 liberates arachidonic acid from the 
membrane, and it is converted to HxA3 and secreted into the lumen via surface MRP2. HxA3 forms a concentration gradient that attracts neutrophils 
across the epithelial layer into the lumen, where they cause inflammatory damage and pathology. Of note, FAAH metabolism of NAEs yields arachidonic 
acid and may also feed into the proinflammatory MRP2/HxA3 pathway.
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organization of P-gp/EC to maintain homeostatic conditions 
can be rapidly reversed by apical inflammatory signal(s) through 
processes involving MRP2/HxA3 that are independent of neutro-
phil function in the submucosal compartment.
Discussion
Identification of a functional P-gp/EC antiinflammatory pathway 
that opposes the proinflammatory MRP2/HxA3 axis and controls 
neutrophil transmigration provides a potential explanation for sev-
eral poorly understood biological and clinical observations. P-gp 
was originally identified as a xenobiotic efflux pump (45), and no 
endogenous substrates have heretofore been identified. Previous 
in vitro studies examining the impact of AEA on P-gp function were 
interpreted as inhibiting the function of this efflux pump (46), but 
these data are consistent with the possibility that AEA can function 
as a P-gp substrate. We now show NAE-type ECs to be endogenous 
substrates for P-gp. Our finding that antiinflammatory NAE secre-
tion from epithelial cells depends on P-gp also provides a poten-
tial mechanism underlying both the development of spontaneous 
intestinal inflammation in P-gp–deficient mice (22) and the clinical 
evidence that P-gp dysfunction contributes to IBD (20).
Previous studies have demonstrated suppression of coli-
tis symptoms by CB2 agonists (42–44); demonstration of P-gp 
secretion of NAE-type ECs that can suppress neutrophil tran-
sepithelial migration, coupled with the observation that CB2-
deficient mice demonstrated an increase in this same process, 
mechanistically links these findings to a specific role for NAE-
type ECs and CB receptor function during intestinal disease. 
Previous studies have suggested that ECs or CB2 ligands can 
reduce neutrophil migration (33, 34), but the same studies also 
showed induction of neutrophil migration by AEA and 2-AG 
(34), leaving the true function in vivo an open question (47). We 
did not observe any chemoattractant activity of ECs alone; all of 
our studies were consistent with inhibition of neutrophil tran-
sepithelial migration in the colon by NAE-type ECs that func-
tioned at least partially via CB2 agonism. The present results 
may also provide a possible mechanistic explanation for anec-
dotal data from colitis patients suggesting clinical benefits from 
exposure to cannabinoids (48).
The present studies have identified a new layer of regulation 
of neutrophil function in the intestine. Unlike other antiinflam-
matory lipids, such as the specialized proresolving mediators that 
are produced by immune cells (49), ECs appear to be secreted 
locally at the apical surface by epithelial cells and can therefore 
constitutively maintain an antiinflammatory environment during 
intestinal homeostasis. Modulation of MRP2/HxA3 and P-gp/EC 
function at the luminal surface of the intestine represents an excit-
ing new avenue for development of topical therapeutics for the 
treatment of IBD. The MRP2/HxA3 pathway is conserved in infec-
tious and noninfectious lung inflammation (4, 9, 50), suggesting 
that the P-gp/EC pathway may similarly regulate inflammation at 
other mucosal surfaces. Additionally, other neutrophil-like cell 
types, such as granulocytic myeloid–derived suppressor cells 
involved in T cell tolerance, have also been shown to be involved 
in inflammatory events associated with IBD (51). It will be inter-
esting to examine the potential for the P-gp/EC and MRP2/HxA3 
axes described herein to regulate their actions.
(Supplemental Figure 7). CB2 agonists have been demonstrated to 
provide beneficial effects in colitis (42–44), and we hypothesized 
that CB2-deficient mice would be less able to respond to the P-gp–
secreted inhibitory NAE-type ECs. In support of this hypothesis, 
Cnr2–/– mice treated with DSS were more vulnerable to inflamma-
tion and developed increased intestinal pathology and weight loss 
compared with WT mice (Figure 6, A–C). In particular, Cnr2–/– mice 
displayed dramatic increases in neutrophil influx into the intestinal 
lumen (Figure 6, C and D), while neutrophil accumulation in the 
tissue was similar in both groups (Figure 6, E–H). As was observed 
during blockade of normal neutrophil transepithelial migration dur-
ing DSS-induced colitis using probenecid to inhibit MRP2 (Figure 
1), neutrophil migration specifically across the epithelium into the 
lumen was associated with significant tissue damage that contrib-
uted independently to disease pathology (Figure 6). The enhanced 
susceptibility of Mdr1a–/– and Cnr2–/– mice to intestinal inflammation 
suggests that absence of a functional P-gp/EC-signaling pathway 
perturbs homeostasis, leading to increased vulnerability to onset 
and possibly maintenance of an inflammatory state.
The development of inflammation in Mdr1a–/– mice depends 
specifically on the absence of P-gp in the epithelial compartment 
(22), consistent with our model in which epithelial P-gp export of 
NAE-type ECs blocks inflammation. In order to confirm that the 
increased susceptibility of Cnr2–/– mice to intestinal inflammation 
resulted from a failure of neutrophils to respond to EC inhibition, 
we created heterologous BM chimeras and evaluated the relative 
contributions of CB2 in the immune and nonimmune compart-
ments to susceptibility to DSS-induced colitis. Overall, mice trans-
planted with Cnr2–/– BM, regardless of recipient genotype, dis-
played the greatest weight loss and colon shortening, indicative of 
increased inflammation (Figure 6, I and J). Transfer of WT BM into 
Cnr2–/– recipients partially abrogated the inflammatory phenotype, 
as these heterologous mice developed less inflammation than seen 
in transfer of Cnr2–/– BM donors into Cnr2–/– recipient controls (Fig-
ure 6, I–K). While this experiment did not fully rule out a potential 
role for CB2 in epithelial or other stromal cells, the data are con-
sistent with our hypothesis in suggesting that CB2 expression on 
radiation-sensitive immune cells plays a dominant role in prevent-
ing development of colitis via inhibitory signaling by ECs.
In sum, these studies have defined an antiinflammatory 
P-gp/EC pathway that acts to counterbalance the proinflamma-
tory MRP2/HxA3 axis. We propose that balancing the P-gp/EC and 
MRP2/HxA3 axes is a mechanism by which epithelial cells them-
selves integrate signals from the local environment to maintain 
exquisite control over the initiation of neutrophil-mediated inflam-
mation. While multidrug-resistant transporters are generally stud-
ied for their role in exporting drugs and foreign compounds from 
the cell, our results indicate that these efflux pumps expressed at 
the apical surface of intestinal epithelial cells provide a critical link 
in communication between sentinel functions of mucosal barri-
ers and the immune system. In fact, by exporting bioactive lipids 
to regulate neutrophil transepithelial migration, MRP2 and P-gp 
uniquely control a critical step of the inflammatory cascade (Figure 
7). It should be noted that the polarized organization of the P-gp/
EC and MRP2/HxA3 axes at the apical surface of intestinal epithe-
lial cells is presumed to be critical for either suppressing or stimu-
lating neutrophil transepithelial migration. This apically restricted 
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 0 5 2 jci.org   Volume 128   Number 9   September 2018
natants collected over the course of 5 hours were pooled from 30 flasks, 
lyophilized, suspended in water, and ultrafiltered through an Amicon 
1,000 Da cutoff membrane (MilliporeSigma) with N2-positive pressure. 
Samples were desalted and captured on a C18 Bakerbond SepPak column 
that was washed with water and then hexane prior to elution with metha-
nol, dried under N2 gas, and stored at –80°C. Before use in migration 
experiments, samples were suspended in HBSS+/+ as needed. Individual 
batches of AMEND were tested for activity in control assays before exper-
imental use and were generally used at a 1:100 to 1:200 final dilution. For 
screening in the DiscoveRx GPCR β-arrestin activity assay, samples were 
suspended in PBS to provide a ×1,000 solution for screening.
Preparation of the human organoid-derived epithelial monolay-
ers. Human intestinal epithelial cells were obtained from patients 
undergoing medically required surgical resections as determined by 
a licensed physician, as described previously (52, 53), with modifica-
tions. The present studies used cells isolated from healthy margins, 
as verified by a pathologist, of tissue resected from the ascending 
colon to obtain intestinal crypts. After washing once in ice-cold 1× PBS 
(Thermo Fisher Scientific), tissue strips were cut and incubated at 4°C 
for 30 minutes in a dissociation buffer consisting of 1× PBS, penicillin/
streptomycin (Thermo Fisher Scientific), 1 mM dithiothreitol (Sigma-
Aldrich), and 0.5 mM EDTA (Sigma-Aldrich). Tissue samples were 
then vigorously shaken to promote epithelial cell dissociation from the 
basement membrane, with this procedure being repeated 5 times to 
collect multiple fractions containing intestinal crypts that were further 
processed and then plated in Matrigel as previously described (53). 
Intestinal crypt–derived organoids were incubated in humidified 5% 
CO2 at 37°C in media that consisted of a 1:1 ratio of stem cell media 
and L-WRN–derived (ATCC CRL-3276) conditioned media (54). Cul-
ture medium was replenished every other day, with organoids being 
passaged every 7 to 9 days using standard trypsin-based techniques. 
Approximately 2.0 × 106 cells/ml were plated in Matrigel to ensure 
robust organoid propagation.
Single-cell suspensions derived from organoids were plated at 1.0 
× 106 cells/ml on polyethylene terephthalate membrane Transwell 
inserts having a 0.4 μm pore size (Corning) and incubated in 1:1 stem 
cell/L-WRN media at 37°C with 5% CO2 (55). Culture medium was 
changed every other day until confluence was reached as determined 
by transepithelial electrical resistance (TEER) monitoring and micro-
scopic observation. At 48 hours prior to each experiment, the basolat-
eral media were replenished with fresh 1:1 stem cell/L-WRN media. 
Medium in the apical chamber was replaced with complete DMEM 
plus 5 μM of the γ-secretase inhibitor IX (DAPT; Calbiochem) to pro-
mote cell differentiation (55). On the day of each experiment, mono-
layers were washed with 1× PBS and both the apical and basolateral 
media were replaced with DMEM lacking phenol red; monolayers 
were incubated for at least 2 hours before initiation of an experiment.
Collection of AMEND from human organoid–derived epithelial mono-
layers. Confluent organoid monolayers grown on polyethylene tere-
phthalate membrane Transwell inserts in 24-well plates were washed 
and equilibrated in HBSS+/+ at 37°C, 5% CO2 for 30 minutes. At the 
end of the equilibration step, supernatants from the apical and baso-
lateral compartments were collected and stored at 4°C as the 0 hours 
samples. Liquid was replaced in both apical and basolateral compart-
ments with 50 μM verapamil in 0.5% DMSO/HBSS+/+ in treated wells 
or DMSO/HBSS+/+ alone in control wells. Verapamil was added to both 
the apical and basal chambers, since this molecule would equilibrate 
Methods
Human cell lines. T84 intestinal epithelial cells at passages 50–79 (ATCC) 
were grown in a mixture of DMEM and Ham’s F12 Nutrient Mixture 
(Thermo Fisher Scientific) supplemented with 14 mM NaHCO3, 15 mM 
HEPES buffer (pH 7.5), 40 mg/l penicillin, 8 mg/l ampicillin, 90 mg/ 
l streptomycin, and 5% heat-inactivated FBS. HCT-8 colon carcinoma 
cells (ATCC) and H292 lung epithelial carcinoma cells (CRL 18-48; 
ATCC) were grown in RPMI 1640 with 10% heat-inactivated FBS.
Salmonella infection of HCT-8 epithelial cells. HCT-8 cell monolay-
ers were grown and maintained on inverted 0.33 cm2 ring-supported, 
collagen-coated 5 μm pore polycarbonate filters or 96-well HTS Tran-
swell filter plates (Costar Corp.). Cells were treated apically and baso-
laterally with probenecid conjugate at 100 μM in HBSS with Ca2+ and 
Mg2+ (HBSS+/+) incubated for 1 hour at 37°C. Following washing, cells 
were infected apically with Salmonella enterica serovar typhimurium 
strain SL1344 (SL) at an MOI of 375 for 1 hour. Following extensive 
washing, neutrophils (1 × 106) were added to the basolateral surface, 
allowed to transmigrate across the monolayer for 2 hours, and quanti-
fied as described below.
Production of enriched HxA3. The extraction protocol and purity of 
HxA3 have been previously reported by the authors of this report (2, 4, 
5). Briefly, to induce HxA3 efflux, Pseudomonas aeruginosa strain PA01 
was grown aerobically in Luria broth (LB) broth overnight at 37°C. 
Cultures were washed once in HBSS+/+ and suspended at a concentra-
tion of 6 × 107 bacteria/ml. H292 monolayers in 162 cm2 flasks were 
infected for 1 hour, washed with HBSS, and then incubated in HBSS+/+ 
for 5 hours. Collected supernatants were captured by reversed phase 
chromatography on octadecylsilane (C18) columns (Supelco; Sigma-
Aldrich), washed with water, and eluted with methanol. Samples were 
stored at –20°C and the volume necessary for individual experiments 
dried down and suspended in HBSS+/+ as needed. Each new batch of 
enriched HxA3 was quality tested before use in experiments and was 
generally used after a 1:4 to 1:8 dilution.
Generation of P-gp knockdown T84 cell lines. shRNA constructs 
targeting the MDR1a gene were generated from a pLK0.1 plasmid 
background and the DNA sequences used were derived from the 
TRC-Hs 1.0 (human) shRNA library, which is publicly available and 
searchable based on the TRCN identifier at the Genetic Perturba-
tion Platform (https://portals.broadinstitute.org/gpp/public/clone/
search). Constructs are from the TRC-Hs 1.0 (human) shRNA library 
and are publicly available, constructs were as follows: B4 (clone 
TRCN0000059683), B5 (clone TRCN0000059684), B6 (clone 
TRCN0000059685), B7 (clone TRCN0000059686), and B8 (clone 
TRCN0000059687). Lentiviruses were produced by transfecting 
packaging cells (293T) with psPAX2, pMD.2G, and pLK0.1 plasmid 
constructs, using Trans-IT-LT1 lipid (Mirus Bio). After 48 hours, lenti-
viral supernatants were harvested, combined with 8 μg/ml polybrene 
(Sigma-Aldrich), and applied to T84 cells in 20% confluent monolay-
ers. This process was repeated 24 hours later, and 48 hours following 
the second transfection, resistant cells were selected with 5 μg/ml 
puromycin. Once stably transfected lines were obtained, reduction 
of P-gp expression was confirmed by Western blot using anti–P-gp 
monoclonal antibody C219 (catalog 517310, EMD Millipore).
Production of enriched AMEND. T84 cells were grown as confluent 
monolayers in 162 cm2 flasks and equilibrated in HBSS+/+ at 37°C, 5% 
CO2. For verapamil treatment of cells, 40 μM verapamil hydrochloride 
(MilliporeSigma) was included during the entire incubation. Cell super-
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Eth), CAS No 942069-11-6, was used at 0.005 mg/ml. OEA, CAS no. 
111-58-0, was used at 0.01 mg/ml. 2–Palmitoyl glycerol (2-PG), CAS no. 
23470-00-0, was used at 0.05 mg/ml. 2-Oleoyl glycerol (2-OG), CAS 
no. 3443-84-3, was used at 0.002 mg/ml. PEA, CAS no. 544-31-0, was 
used at 0.0000005 mg/ml. Arachidonic acid, peroxide-free formu-
lation (pfAA), CAS no. 506-32-1, was used at 0.125 mg/ml. NADA (a 
potent endogenous cannabinoid and vallinoid receptor agonist), GP1a (a 
selective CB2 receptor agonist), and JTE 907 (a selective CB2 receptor 
inverse agonist), were purchased from Tocris Bioscience.
LC/MS analysis of AMEND. MeOH-eluted preparations as above 
were dried under a stream of N2(g), suspended in MeOH/buffer, 
and separated by HPLC using a Vydac (Hichrom) C18 (10 um; 300 
Å) semi-preparative column (10 × 250 cm). Active AMEND frac-
tions were characterized by HPLC/MS (Genesis C18 (4 μm, 120 Å) 
analytical HPLC column (4.6 × 150 mm) equilibrated with 5 mM 
triethylamine acetic acid (pH 7.2), with the effluent analyzed by using 
a Finnigan LCQ Deca electrospray mass spectrometer.
Selected samples were analyzed for high mass accuracy determi-
nation and solubilized in 50:50 acetonitrile/H2O with 0.2% formic 
acid. A MAXIS-HD ultra-high resolution quadrupole time-of-flight 
(UHR-ESI-QTOF) mass spectrometer (Bruker Daltonik GmbH) was 
used; this was coupled to a syringe driver (Hamilton) with the sample 
solution being infused at a rate of 3 μl/min.
Nitrogen acted as the nebulizing gas, applied at a pressure of 2 
bar. The drying gas was also nitrogen, supplied at a flow rate of 8 l/
min and a temperature of 200°C. Positive ion mode was used with a 
corresponding capillary voltage of –4500 V. Only full scan data were 
acquired. For each batch of samples, a solution of 5 mM sodium for-
mate clusters was also analyzed. This acted as an external data file 
calibrant over the mass range 75–1000 m/z. The recalibrated detected 
mass and isotope pattern were used in the FindFormula tool to gener-
ate a list of potential theoretical formulae within 2 mDa of the detected 
mass. The detected isotope pattern was used to sort this list.
Data acquisition and automated processing were controlled via 
Compass OpenAccess 1.7 software (Bruker Daltonik GmbH), and data 
processing was carried out using DataAnalysis 3.4 (Bruker Daltonik 
GmbH). At each step, care was taken to avoid sample degradation and 
oxidation by maintaining samples on ice and under N2 gas as much 
as possible. Relative quantification by ion intensities was performed 
by the summation of intensities for protonated and sodiated ions to 
compensate for possible variation in adduct formation due to varying 
biological sodium levels.
Preparation of dextran conjugates. Dextran (40 kDa) was oxidized 
with NaIO4 in 0.1 M sodium acetate (pH 5.0). After dialysis against 
H2O, the oxidized dextran was reacted with excess 1,6,-diaminohexane 
and coupled via reductive amination at pH 9.5 by the addition of sodi-
um borohydride. After a second dialysis against H2O, reaction with 1- 
fluoro-2,4-dinitrobenzene was used to determine the presence of 
approx imately 21 free NH2 groups per molecule of diaminohexane-mod-
ified dextran. N-(3-dimethylamino propyl)-N′-ethylcarbodiimide HCl 
was used to covalently couple probenecid (11/dextran molecule) or ben-
zoic acid (13/dextran molecule), with the products being dialyzed against 
water, lyophilized, and stored at –20 °C.
Mouse experiments. C57BL/6 WT and Cnr2–/– mice were purchased 
from Jackson Laboratories; FVB WT and Mdr1a–/– mice were purchased 
from Taconic. Female mice were used at age 6 to 12 weeks, and geno-
types were mixed for 2 to 4 weeks prior to experiments to equalize the 
in such a closed system. Supernatants from the apical compartment 
were collected and replaced with 0.5% DMSO/HBSS+/+ with or with-
out 50 μM verapamil every 2 hours up to 6 hours to monitor the efflux 
of AMEND. To assess accumulation of AMEND in the basolateral 
chamber of this model, supernatants from the basolateral compart-
ment were collected and replaced with 0.5% DMSO/HBSS+/+ with or 
without 50 μM verapamil at 0 and 6 hours. Cells were maintained at 
37°C, 5% CO2 throughout the experiment. Samples were pooled from 
replicate wells for each compartment, apical and basolateral, and cen-
trifuged at 1,452 g for 15 minutes at 4°C to remove cell debris. Superna-
tants were stored at –20°C prior to LC/MS analysis of AMEND. Data 
are shown as mean ± SD from 3 independent experiments with 12–24 
technical replicates in each experiment. TEER values (mean ± SD) 
for each independent experiment are as follows: (a) 492.91 ± 88.7; (b) 
441.01 ± 45.87; and (c) 447.91 ± 19.93.
96-Well neutrophil migration. Peripheral blood neutrophils from 
healthy human volunteers were purified from acid-citrate-dextrose 
anticoagulated peripheral blood by 2% gelatin sedimentation, as pre-
viously described (14). Red blood cells were removed by lysis in cold 
NH4Cl buffer, and neutrophils were washed with HBSS–/– (without 
Ca2+ or Mg2+) and suspended to a final volume of 5 × 107/ml. 96-Well 
HTS Transwell filter plates (Corning), 3 μm pore size, were coated with 
0.1 mg/ml rat tail collagen and allowed to dry overnight. Enriched 
HxA3 (see above) was added to the lower compartment along with a 
final 1:10 dilution of vehicle control, enriched AMEND (see above), 
or purified EC compounds at the indicated concentrations. Neutro-
phils (5 × 105) were added to the top well along with a final 1:10 dilu-
tion of vehicle or purified ECs, placed in a 37°C incubator with 5% 
CO2, and allowed to migrate for 2 hours. Top wells were removed, and 
transmigrated neutrophils were lysed with 1% Triton X-100. Sodium 
citrate buffer (0.1 M, pH 4.2) was added, and an equal volume of 2,2′- 
azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) in 0.1 M 
sodium citrate was added to samples. MPO activity was measured, 
and neutrophil cell equivalents were calculated by comparison with 
a standard curve, with data from individual experiments being nor-
malized to 100% HxA3-driven migration. Data are shown as mean ± 
SEM from at least 3 independent experiments. Statistical analysis was 
performed using GraphPad Prism; data were analyzed by either 1-way 
ANOVA or Mann-Whitney nonparametric U test, as appropriate for 
experimental conditions.
Purified compounds used in migration assays. All compounds were 
obtained from Cayman Chemical and suspended at the highest con-
centration at which they were soluble in PBS (based on the manufac-
turer’s instruction and empirical observation) and then diluted 1:10 to 
final concentrations as indicated:
Arachidonoyl ethanolamide (AEA), Chemical Abstracts Service 
(CAS) no. 94421-68-8, was used at a final concentration of 0.01 mg/ml. 
α-LEA, CAS no. 57086-93-8, was used at 0.005 mg/ml. LEA, CAS no. 
68171-52-8, was used at 0.0001 mg/ml. γ-LEA, CAS no. 150314-37-7, 
was used at 0.0001 mg/ml. 2-AG, CAS no. 53847-30-6, was used at 0.01 
mg/ml. 2-Linoleoyl glycerol (2-LG), CAS no. 3443-82-1, was used at 0.01 
mg/ml. 2-(14,15-Epoxyeicosatrienoyl) glycerol, CAS no. 848667-56-1, 
was used at 0.005 mg/ml. NAE, CAS no. 94421-69-9, was used at 0.005 
mg/ml. O-Arachidonoyl ethanolamine (O-AEA), CAS no. 443129-35-9, 
was used at 0.001 mg/ml. NE, CAS no. 222723-55-9, was used at 0.001 
mg/ml. 12-Hydroxyeicosatetraenoic acid (12-HETE), CAS no. 71030-
37-0, was used at 0.005 mg/ml. 20-HETE ethanolamide (20-HETE 
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Mass spectrometric analysis of HXA3 in colonic mucosa. C57BL/6 mice 
were administered 5% DSS in their drinking water and sacrificed on day 7. 
The proximal colon from untreated or DSS-treated mice (9 mice/cohort) 
was harvested, and 3 intestinal segments were pooled. Mucosal scrapings 
were collected by scraping intestinal surfaces with a rubber policeman in 
PBS, and HxA3 content was analyzed as previously described (17).
Statistics. Data from the DSS studies (Figures 1 and 6) are repor-
ted as mean ± SEM, n = 10 mice per group, statistical significance 
by Mann-Whitney 1-tailed nonparametric U test. Data from the 
polymorphonuclear leukocyte (PMN) transmigration assays using 
peripheral human blood neutrophils (Figures 2 and 3A) are reported 
as mean ratios ± SEM of 3 independent experiments with statistical 
significance by 1-way ANOVA. Data from human organoid–derived 
epithelial monolayers (Figure 3, B and C) are reported as mean ± 
SD from 3 independent experiments with 12–24 technical replicates 
in each experiment, with statistical significance determined by 
unpaired (2 tailed) t test. Experiments assessing the AMEND pres-
ent in mouse tissue (Figure 4) are reported as mean ± SEM from 3 
independent experiments, with statistical significance determined 
by 1-way ANOVA. Finally, BM migration assays (Figure 5) are repor-
ted as mean ± SD from 3 independent experiments. Comparison of 
groups was performed by Mann-Whitney nonparametric U test. P ≤ 
0.05 was considered significant.
Study approval. The care of all animals used in this study and 
animal experiments performed were in accordance with the Univer-
sity of Massachusetts Medical School IACUC (protocol 1993-12). All 
neutrophil-based studies were approved by the IRB of the University 
of Massachusetts Medical School (protocol 13006). Human organoid– 
derived sample collection was approved by the IRB of Massachusetts 
General Hospital (protocol 2015P001908). All subjects provided 
informed consent prior to participation in these studies.
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microbiota. Mice were treated with 3% DSS (molecular weight 36,000–
50,000; MP Biomedicals) in the drinking water for 7 days, then placed 
back on normal water and sacrificed at day 9, which represented peak 
disease state. Samples from mid and distal colon were fixed in 10% for-
malin, paraffin-embedded, sectioned, and stained for histopathological 
analysis with H&E. Each sample was graded semiquantitatively from 
0 to 3 for 4 criteria: (a) degree of epithelial hyperplasia and goblet cell 
depletion; (b) leukocyte infiltration in the lamina propria; (c) area of tis-
sue affected; and (d) presence of markers of severe inflammation, such 
as crypt abscesses, submucosal inflammation, and ulcers. Samples were 
scored by a trained investigator blinded to sample identity, and mid and 
distal colon values were averaged to give a colon histopathology score.
Isolation of neutrophils from mouse BM. Neutrophils were isolated 
from femurs and tibias as described in Mócsai et al. (56), with the fol-
lowing modifications: neutrophils were isolated in HBSS/HEPES with-
out FCS, and red blood cell lysis was performed with ACK lysis buffer 
for 4.5 minutes. A total of 1 × 106 mouse neutrophils were added to the 
top well of a 96-well migration plate and allowed to migrate in the baso-
lateral to apical direction across Salmonella-infected HCT8 epithelial 
cells. Neutrophil migration was quantified by ABTS assay as above.
Creation of BM chimeras. C57BL/6 WT and Cnr2–/– mice were lethally 
irradiated (90–100 Gy) and reconstituted with a total of 107 donor BM 
cells from C57BL/6 WT or Cnr2–/–. Mice were allowed to reconstitute for 
7 weeks before induction of DSS colitis. Approximately 85%–90% recon-
stitution of donor BM was achieved in this experiment.
Isolation of lamina propria leukocytes and flow cytometry. Cell sus-
pensions from the lamina propria were prepared as described previ-
ously (57). Intestinal tissue was cut into small pieces, treated with 
RPMI with 10% FBS and 5 mM EDTA to remove epithelial cells, and 
then incubated with 100 U/ml Collagenase Type VIII (Sigma-Aldrich) 
for two 1-hour periods. Cells were then applied to a discontinuous 
30%/40%/75% gradient of Percoll (GE Healthcare Life Sciences) 
and harvested from the 40%/70% interface. Cells were washed in 
PBS/0.1% BSA, incubated with anti-Fc receptor (αCD16/32, catalog 
14-0161-81; eBioscience), and stained with Zombie Live/Dead infra-
red stain (eBioscience), then surface stained with antibodies to CD45 
(clone 30-F11, catalog 103130, 103127, 103105), CD11b (clone M1/70, 
catalog 101236), Ly6G (clone HK1.4, catalog 128025; and clone 
127609, catalog 127618), and Ly6C or Gr1 (clone RB6-8C5, catalog 
108407). Samples were run on a MACSquant Analyzer 10 (Miltenyi 
Bioscience) and analyzed using FlowJo software, version 10 (Treestar).
Analysis of MPO content in mouse samples. Samples were assayed for 
MPO activity as described (56). Tissue sections of colon were frozen 
in liquid N2 and stored at –80°C until use. Sections were put in hexa-
decyltrimethylammonium bromide (HTAB) (MilliporeSigma) buffer 
with lysing matrix D (MP Biomedicals) and homogenized with a Fast-
Prep-24 homogenizer at level 6 for 40 seconds. Samples were com-
bined with ADHP and fluorescence read over 8 minutes. Slopes were 
calculated by linear regression using Graphpad Prism and normalized 
to protein content for individual samples as measured by detergent- 
tolerant DC protein assay (Bio-Rad). For analysis of fecal samples, fecal 
contents were weighed and HTAB buffer added at a ratio of 10 μl/mg. 
Calculated slopes were used directly.
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